Biologics targeting vascular endothelial growth factor (anti-VEGF) have revolutionized the treatment of retinal diseases causing altered vascular permeability, such as diabetic macular oedema, retinal vein occlusion and the neovascular type of age-related macular degeneration (nAMD). This evidence concerns the gene VEGFA and age-related macular degeneration.